Literature DB >> 15909088

[Occurrence of chloroquine-induced myopathy after low-dose treatment of rheumatoid arthritis for seven years].

A Haberl1, P Fischer, D Pongratz, J P Sieb.   

Abstract

The myotoxicity of chloroquine and hydroxychloroquine has been known for decades. Limb-girdle weakness due to a vacuolar myopathy may occur occasionally in a dose-dependent manner during the first 24 months on chloroquine. However, we report on a case in which muscular weakness developed after a daily intake of 250 chloroquine phosphate (= 155 mg chloroquine base) for a period of 7 years. Even after long-term and apparently well-tolerated chloroquine treatment, the occurrence of severe side-effects is possible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15909088     DOI: 10.1007/s00393-005-0576-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  7 in total

1.  CHLOROQUINE NEUROMYOPATHY.

Authors:  J P WHISNANT; R E ESPINOSA; R R KIERLAND; E H LAMBERT
Journal:  Proc Staff Meet Mayo Clin       Date:  1963-11-06

2.  Experimental myopathy induced by amphiphilic cationic compounds including several psychotropic drugs.

Authors:  D Drenckhahn; R Lüllmann-Rauch
Journal:  Neuroscience       Date:  1979       Impact factor: 3.590

3.  Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature.

Authors:  J Müller-Höcker; H Schmid; M Weiss; U Dendorfer; G S Braun
Journal:  Hum Pathol       Date:  2003-03       Impact factor: 3.466

4.  Chloroquine neuromyopathy associated with keratopathy and retinopathy.

Authors:  A Erringer; P Colville
Journal:  Br Med J       Date:  1967-04-22

5.  Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature.

Authors:  J A Avina-Zubieta; E S Johnson; M E Suarez-Almazor; A S Russell
Journal:  Br J Rheumatol       Date:  1995-02

Review 6.  Iatrogenic and toxic myopathies.

Authors:  Joern P Sieb; Thomas Gillessen
Journal:  Muscle Nerve       Date:  2003-02       Impact factor: 3.217

7.  Chloroquine neuromyotoxicity. Clinical and pathologic perspective.

Authors:  M L Estes; D Ewing-Wilson; S M Chou; H Mitsumoto; M Hanson; E Shirey; N B Ratliff
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

  7 in total
  2 in total

1.  Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy.

Authors:  J Finsterer
Journal:  Acta Neurol Belg       Date:  2020-11-23       Impact factor: 2.396

Review 2.  [Myasthenia gravis and myasthenic syndromes].

Authors:  W Marouf; J P Sieb
Journal:  Z Rheumatol       Date:  2009-08       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.